Athersys: Down But Not Out - An Interview With CEO Van Bokkelen
- Shares Battered After Failure to Show Efficacy in Ulcerative Colitis (UC) Phase II.
- CEO Van Bokkelen Answers the Tough Questions Including: Why No Recent Insider Buying?
- The Science Behind Multistem Stroke Therapy.
- Efficacy in Stroke Trial Unleashes Tremendous Value.